Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Trastuzumab Biosimilars Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for trastuzumab biosimilars has seen explosive expansion in recent years. Projected to climb from $6.9 billion in 2025 to $8.86 billion in 2026, it is set to achieve a compound annual growth rate (CAGR) of 28.5%. Historical growth during this timeframe was driven by the elevated prevalence of HER2-positive breast cancer, the expiration of trastuzumab’s patent protection, increasing expenses associated with oncology medications, the establishment of regulatory frameworks for biosimilars, and their growing acceptance within hospital oncology departments.
The trastuzumab biosimilars market is projected to experience significant expansion over the coming years, reaching a valuation of $24.48 billion by 2030 with a compound annual growth rate (CAGR) of 28.9%. This anticipated growth during the forecast period is driven by factors such as a rising incidence of cancer, the widening application to gastric cancer indications, supportive reimbursement policies for biosimilars, increased confidence among physicians, and ongoing efforts to curb healthcare expenses. Key developments shaping this forecast period include the swift adoption of oncology biosimilars, enhanced accessibility to HER2-targeted therapies, intensified price competition within breast cancer treatment, an expanded role for hospital-based oncology treatments, and growing endorsement of biosimilar interchangeability.
Download A Free Sample Report For Comprehensive Market Insights:
#Trastuzumab Biosimilars Market Growth Factors: Which Forces Are Supporting Market Expansion?
The market for trastuzumab biosimilars has experienced growth due to the increasing incidence of breast and gastric cancer. This type of biosimilar is employed to treat HER2-overexpressing breast cancer and metastatic gastric cancer. As an example, data from September 2023 published by the American Cancer Society, a U.S. nonprofit organization focused on cancer eradication, indicated that roughly 297,790 new invasive breast cancer cases were expected among women in 2023, with around 43,700 fatalities from the disease that same year. In India, Cancer India reports that breast cancer is the most prevalent cancer among women, representing 14% of all female cancer cases. Consequently, the growing prevalence of these cancers has boosted demand for trastuzumab biosimilars, which provide a more affordable alternative to expensive medications, thus propelling the trastuzumab biosimilars market forward.
Trastuzumab Biosimilars Market Categorization By Product Type And Application
The trastuzumab biosimilars market covered in this report is segmented –
1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy
Trastuzumab Biosimilars Market Industry Trends: What Changes Are Reshaping Demand?
Major industry players continue to drive the trastuzumab biosimilars market by introducing new offerings in previously untapped regions. These companies are pursuing a range of strategic actions—such as developing innovative products, forming alliances, and broadening their geographic presence and product lines—to preserve a competitive edge and more effectively address customer demands. A notable example occurred in April 2024, when Accord BioPharma Inc., a pharmaceutical firm based in the United States, received approval from the U.S. Food and Drug Administration (FDA) for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab) used to treat multiple types of HER2-overexpressing cancers. This medication is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. Although HER2-positive cancers tend to be aggressive, they often respond well to targeted therapies. HERCESSI functions by attaching to the HER2 receptor, curbing its activity and consequently decelerating the division of cancer cells.
Trastuzumab Biosimilars Market Company Landscape And Strategic Competition
Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited
Access The Complete Trastuzumab Biosimilars Market Report:
Trastuzumab Biosimilars Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model